HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multiple Endocrine Neoplasia Type 2a (MEN 2)

A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease.
Also Known As:
MEN 2; MEN II; Multiple Endocrine Neoplasia Type 2; MEA 2a; MEA II; MEA IIa; MEN IIa; MEN-2A Syndrome; MEN2a; Multiple Endocrine Neoplasia, Type IIa; Multiple Endocrine Neoplasms Type 2a; Pheochromocytoma And Amyloid-Producing Medullary Thyroid Carcinoma; MEN 2A Syndrome; MEN-2A Syndromes; Pheochromocytoma And Amyloid Producing Medullary Thyroid Carcinoma; MEN 2a; Neoplasia, Multiple Endocrine Type 2a; Neoplasms, Multiple Endocrine Type 2a; Sipple Syndrome
Networked: 1125 relevant articles (22 outcomes, 97 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Pheochromocytoma
2. Neoplasms (Cancer)
3. Multiple Endocrine Neoplasia Type 2b (MEN 3)
4. Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis)
5. Thyroid Neoplasms (Thyroid Cancer)

Experts

1. Pacak, Karel: 14 articles (06/2017 - 06/2005)
2. Dralle, Henning: 11 articles (01/2022 - 12/2002)
3. Takahashi, M: 10 articles (04/2014 - 01/2000)
4. Eisenhofer, Graeme: 10 articles (05/2012 - 08/2005)
5. Takahashi, Masahide: 8 articles (01/2022 - 04/2002)
6. Iwashita, T: 8 articles (04/2014 - 01/2000)
7. Machens, Andreas: 7 articles (01/2022 - 07/2005)
8. Moley, Jeffrey F: 7 articles (10/2015 - 05/2002)
9. Mannelli, Massimo: 7 articles (05/2014 - 08/2005)
10. Linehan, W Marston: 7 articles (03/2011 - 06/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Multiple Endocrine Neoplasia Type 2a:
1. DNA (Deoxyribonucleic Acid)IBA
2. Pentagastrin (Peptavlon)FDA Link
3. Calcitonin (Calcitonin, Eel)FDA LinkGeneric
4. Codon (Codons)IBA
5. Insulin (Novolin)FDA Link
07/01/1996 - "Furthermore, insulin suppression of FFAs improved with age in men (2% per decade, P < 0.0001) but not in women. "
01/01/1996 - "In conclusion, insulin-mediated MSNA: 1) is neither a response to nor a cause of the vasodilation observed in insulin sensitive men, 2) has no net pressor effect even in the most insulin resistant men in whom insulin-mediated vasodilation was impaired. "
05/01/2017 - "Based on the results of insulin tolerance test (ITT) patients were qualified for one of the following groups: 1) severe GHD - SGHD (26 patients; 8 women and 18 men); 2) partial GHD - PGHD (22 patients, 7 women and 15 men); 3) normal GH status - NGHS (28 patients, 9 women and 19 men). "
05/01/1992 - "We investigated the sensitivity to insulin with a hyperinsulinemic (approximately 719 pM [approximately 100 microU/ml]) euglycemic clamp in two groups of normotensive nonproteinuric IDDM patients; 12 (10 men, 2 women) had high Na+/Li+ CT activity (mean 0.47, range 0.42-0.68 mmol/L red blood cells [RBC]/h, group 1) and 12 (9 men, 3 women) had normal Na+/Li+ CT activity (mean 0.24, range 0.12-0.31 mmol/L RBC/h, group 2). "
03/01/1995 - "Seventeen NIDDM subjects (15 men, 2 women) participated in a randomized, partially blinded, placebo-controlled, crossover trial of three active treatment regimens (nasal insulin, 120 U at 0 min, 60 U at 0 and +20 min or 120 U at +20 min) in relation to a standardized mixed meal given at 0 min. All active treatments significantly reduced postprandial glucose concentrations compared to placebo. "
6. SeleniumIBA
7. SaltsIBA
02/01/1999 - "In 16 African Americans (blacks, 14 men, 2 women) with average admission mean arterial pressure (MAP, mm Hg) 99.9+/-3.5 (mean+/-SEM), we investigated whether NaCl-induced renal vasoconstriction attends salt sensitivity and, if so, whether supplemental KHCO3 ameliorates both conditions. "
02/01/2021 - "Starting with the synthesized Room temperature Ionic Liquid (RT-IL) [nBu3 MeN][B(OMe)3 (CN)], we were able to crystallize the double salt [nBu3 MeN]2 [B(OMe)3 (CN)](CN). "
06/29/2010 - "The sample was taken from the Basic Healthcare Areas of Salt and Banyoles (belonging to the Girona Healthcare Region), the discussion groups being comprised of (a) 6 immigrant Moroccan women, (b) 7 immigrant sub-Saharan African women and (c) 6 immigrant and native population men (2 native men, 2 Moroccan men and 2 sub-Saharan men); and the semi-structured interviews being conducted with the following healthcare professionals: (a) 3 gynaecologists, (b) 3 nurses and 1 administrative staff. "
09/22/2003 - "The isolated salts are stable towards moisture and air and the complexes 2 and 3 were treated with 1,3-bis(diphenylphosphino)propane (dppp) to give the respective substitution products [Bu(3)MeN](2)[(dppp)M(SnB(11)H(11))(2)] (M=Pd, Pt)."
01/01/2011 - "To develop a reliable and accurate preimplantation genetic diagnosis (PGD) method in six families with endocrine diseases: persistent hyperinsulinemic hypoglycemia of infancy (PHHI), congenital adrenal hyperplasia (CAH) salt-wasting form, Sanjat-Sakati syndrome and multiple endocrine neoplasia 2A (MEN 2A). "
8. GlucocorticoidsIBA
9. vandetanib (ZD6474)IBA
10. Sodium Oxybate (gamma Hydroxybutyrate)FDA Link

Therapies and Procedures

1. Thyroidectomy
2. Adrenalectomy
3. Lymph Node Excision (Lymph Node Dissection)
4. Length of Stay
5. Therapeutics